Indeed, mutated or de-regulated master transcription factors are regularly identified as oncogenic drivers in leukemia.[19–27] Mutations in the CEBPA gene are found in 10–15% of de novo acute myeloid leukemia (AML) cases, predominantly in patients with normal karyotype acute myeloid leukemia (NK-AML).[28–30] The mutations are not equally distributed across the CEBPA locus but cluster in two hotspots in different regions of the gene (Figure 1). Here, CEBPA is linked to leukemia.